BeiGene (NASDAQ:ONC) announced Tuesday that the U.S. Food and Drug Administration (FDA) approved its anti-tumor agent ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Beigene, Ltd. (NASDAQ:ONC – Get Free Report)’s stock price gapped down prior to trading on Monday following insider selling activity. The stock had previously closed at $271.80, but opened at $255.83.

Bank of America upgraded shares of Beigene (NASDAQ:ONC – Free Report) from a neutral rating to a buy rating in a report published on Monday morning, MarketBeat.com reports. The brokerage currently has ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and ...

BeiGene, Ltd. (ONC) shares ended the last trading session 3.2% higher at $244.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

If you’re interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to.  According to ...

Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...

In this article, we are going to take a look at where BeiGene, Ltd. (NASDAQ:ONC) stands against the other biotech stocks. No matter the market environment, you’ll always find entertainment in ...